alphaveNATCOPHARM₹818.80

NATCO Pharma Ltd.

₹ CrorePeersDRREDDY ZYDUSLIFE SUNPHARMA LALPATHLAB NEULANDLAB NH SAILIFE COHANCEMcap ₹14,657 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Returns
Return on Common Equity	23.72	24.77	15.38	15.38
Return on Assets	20.10	21.82	12.81	12.81
Return on Capital Employed	26.37	25.51	13.09	13.09
Return on Invested Capital	22.76	21.65	12.37	8.59
Margins
EBITDA Margin	43.80	49.58	35.22	30.19
Operating Margin	39.13	44.27	30.16	30.16
Incremental Operating Margin	—	91.99	208.12	—
Pretax Margin	41.85	51.73	36.55	31.70
Net Income Margin	34.72	42.52	34.78	32.85
Net Income to Common Margin	34.72	42.56	34.78	32.84
FCF Margin	21.33	26.76	33.77	33.77
Additional
Effective Tax Rate	17.04	17.81	7.98	8.21
Dvd Payout Ratio	12.30	5.72	6.36	—
Sustainable Growth Rate	20.80	23.35	14.40	15.38
Incremental Operating Margin %	91.99	208.12	62.99	—

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.